This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (previously presented) A method for the management of incontinence in a patient, wherein the method comprises admitting orally into the patient a dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that releases the member at a controlled and sustained, substantially zero order rate of 0.05 mg per hour up to 0.850 mg per hour for about 24 hours.

2-31. (canceled)

32. (previously presented) A pharmaceutical dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salts, the dosage form being adapted to release the member at a controlled and sustained, substantially zero order release rate for about 24 hours.

33. (canceled)

34. (not entered) A dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about .28 ng/ml to about .45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.

35. (not entered) The dosage form according to Claim 34, wherein said salt is oxybutynin hydrochloride.

36. (not entered) The dosage form of Claim 35, wherein said dosage form delivers at a substantially zero order rate of release.

37. (not entered) The dosage form according to Claim 34, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

38. (not entered) The dosage form according to Claim 35, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

39. (not entered) The dosage form of Claim 34, wherein said dosage form delivers at a substantially zero order rate of release.

40. (not entered) The dosage form according to Claim 34, wherein said dosage form is a tablet.

41. (not entered) The dosage form according to Claim 35, wherein said dosage form is a tablet.

42. (not entered) The dosage form according to Claim 37, wherein said dosage form is a tablet.

43. (not entered) The dosage form according to Claim 38, wherein said dosage form is a tablet.

44. (not entered) A method for the management of incontinence in a patient comprising administration to a subject of a dosage form comprising 5 mg to 250 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, wherein (i) said dosage form provides a maximum plasma oxybutynin concentration of about .28 ng/ml to about .45 ng/ml per mg of said member in said dosage form and (ii) wherein said dosage form delivers said member from said dosage form over a period of about 24 hours.

45. (not entered) The method according to Claim 44, wherein said salt is oxybutynin hydrochloride.

46. (not entered) The method according to Claim 44, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

47. (not entered) The dosage form of Claim 44, wherein said dosage form delivers at a substantially zero order rate of release.

48. (not entered) The method according to Claim 45, wherein said dosage form further comprises a member selected from the group consisting of hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose.

49. (not entered) The dosage form of Claim 48, wherein said dosage form delivers at a substantially zero order rate of release.

50. (not entered) The method according to Claim 44, wherein said dosage form is a tablet.

51. (not entered) The method according to Claim 45, wherein said dosage form is a tablet.

52. (not entered) The method according to Claim 46, wherein said dosage form is a tablet.

53. (not entered) The method according to Claim 48, wherein said dosage form is a tablet.

54. (not entered) The method according to any one of Claims 44, 45, 46, 48, 50, 51, 52 or 53 wherein the incidence of side effects associated with oxybutynin treatment is reduced.